Institution: British Patient Capital
Headquarters: Sheffield, United Kingdom
AUM: £2.5 billion
The Evolution Technology Fund II is targeting $250 million in equity capital, with investments focused on software and cybersecurity companies globally. The fund’s portfolio companies include the likes of CounterCraft, a UK based cybersecurity firm.
British Patient Capital tends to focus its private equity fund commitments on venture capital and growth equity vehicles.
Platinum subscribers may click here for the investor’s full profile, including key contacts, allocation strategy and fund investments.